6533b852fe1ef96bd12ab8e3
RESEARCH PRODUCT
Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis
Enrico CarminaFahimeh Ramezani TehraniMina AmiriRazieh Bidhendi-yarandiRazieh Bidhendi-yarandiSamira Behboudi-gandevanisubject
Adultmedicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulationMyocardial InfarctionMyocardial Ischemia030209 endocrinology & metabolismCoronary Artery DiseaseAngina PectorisAngina03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinePrevalencemedicineHumansMyocardial infarctionRisk factoreducationAgedProportional Hazards ModelsHeart Failureeducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryPolycystic ovary syndrome (PCOS)Hazard ratioObstetrics and GynecologyMiddle Agedmedicine.diseasePolycystic ovaryStrokeCerebrovascular DisordersCardiovascular DiseasesCase-Control StudiesFemalebusinessPolycystic Ovary SyndromeCohort studydescription
This study aimed to evaluate the prevalence (P)/hazard ratio (HR) of cardiovascular (CV) events among reproductive age and menopausal age women with polycystic ovary syndrome (PCOS) in comparison with healthy controls. PubMed, Scopus, ScienceDirect, Web of science, and Google scholar were searched for retrieving observational studies published up to April 2018 investigating CV events in patients with PCOS. The primary outcomes were a composite outcome of CV events [including coronary arterial disease (CAD), cardiovascular disease (CVD), myocardial infarction (MI), angina, heart failure, and ischemic heart disease] and mortality due to CV events; secondary outcomes were specific CVD events, including cerebrovascular disease, CAD, CVD, MI, angina, heart failure, ischemic heart disease, and stroke. In this meta-analysis, both fixed and random effect models were used. Potential sources of heterogeneity were explored by meta-regression and subgroup analyses. Sixteen studies including 12 population-based were analyzed for the meta-analysis. Results showed that the pooled HRs of CV events in PCOS patients of reproductive age and in menopausal/aging women were higher than healthy controls (pooled HR: 1.38, 95% CI: 1.12-1.71) and (pooled HR: 1.53, 95% CI: 1.15, 2.04), respectively. Compared to healthy controls, analysis of population-based studies revealed that the HR of CV events increased only in reproductive age PCOS patients (1.43-fold, 95% CI: 1.27, 1.61), whereas the difference was not statistically significant when comparing menopausal/aging PCOS patients to healthy controls (1.03-fold, 95% CI: 0.41, 2.59). Sufficient data were not available for comparing the HRs of mortality due to CV events between the two PCOS age groups. Mainly based on population-based study, we found a greater risk of CV events in reproductive aged but not in menopausal/aging PCOS women, suggesting that having a history of PCOS during reproductive ages may not be an important risk factor for developing events in later life. This is a preliminary assumption and needs to be reevaluated by further comprehensive cohort studies of longer duration, initiated in the reproductive period, considering all known CVD risk factors.
year | journal | country | edition | language |
---|---|---|---|---|
2019-08-06 | Gynecological Endocrinology |